LL-37 dosing schedule
> Updated:
Calculate the LL-37 dose
The calculator is already set up for LL-37 — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 100 mcg subcutaneously, once daily | Starting dose |
| Maintenance | 100–300 mcg subcutaneously, once daily | Increase if needed |
| Upper range | up to 400 mcg subcutaneously per day; 4–12 week cycle | Maximum in this schedule |
The scientific context for this compound, from structure to published studies, is collected in the monograph.
Practical dosing and effect details
LL-37 is the C-terminal fragment of human cathelicidin hCAP18, and like most host-defense peptides, it is broken down quickly by serum and tissue proteases. That is a general pharmacological property of this class of molecules, not a finding from one specific clinical trial: a short circulating half-life in active form is the main reason research protocols favor daily subcutaneous administration in small amounts rather than a rare large dose. The schedule on this page (100 mcg starting dose, 100 to 300 mcg maintenance, up to 400 mcg upper limit over a 4 to 12 week cycle) follows that same logic: raising the dose gradually lets tolerance be assessed at each step before moving to the next level, instead of starting at the maximum. Direct clinical data on LL-37 in humans remain limited, so the figures above are a summary from public sources and protocols, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 5 mg vial.LL-375 mg+ 2 mlDiluent
- 2Get the concentrationExample: 5 mg in 2 ml =LL-372.5 mg/ml(2,500 mcg/ml)
- 3Work out the volume per doseFor example, for a 0.1 mg dose:0.1 mg = 0.04 ml= 4 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
LL-37: reference regimens
Controlled data on this compound are limited.
LL-37 is an antimicrobial peptide that research and protocol sources administer subcutaneously (SubQ).
LL-37 dosing in the sources this page draws on is given as a range (100–400 mcg subcutaneously per day), not a fixed figure: the exact value in each protocol depends on cycle length and the specific research goal.
More scientific background in the LL-37 monograph
Notes and safety
- • LL-37 is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
LL-37